Finance

Lists
Q910:FRA
Annexin Pharmaceuticals AB (publ)
0,77 €
-0,26%
(-0,0020) 1D
9-окт., 22:00:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for Q910...
Open
0,77 €
High
0,77 €
Low
0,77 €
Mkt. cap
79,16 млн
Avg. vol.
70,00
Volume
0,00
52-wk high
2,58 €
52-wk low
0,76 €
No. of employees
4
Open
0,77 €
High
0,77 €
Low
0,77 €
Mkt. cap
79,16 млн
Avg. vol.
70,00
Volume
0,00
52-wk high
2,58 €
52-wk low
0,76 €
No. of employees
4
News stories
From web sources and news partners
About Annexin Pharmaceuticals AB (publ)
CEO-
Employees4
Founded2014
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in SEK
Loading Previous Earnings...
Revenue
Net income
All values in SEK
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
7,05 млн
8,00 млн
7,92 млн
8,48 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,35 млн
2,26 млн
2,90 млн
2,96 млн
Operating expense
9,40 млн
10,26 млн
10,82 млн
11,14 млн
Total operating expenses
9,40 млн
10,26 млн
10,82 млн
11,14 млн
Operating income
-9,40 млн
-10,26 млн
-10,82 млн
-11,14 млн
Other non operating income
-
-
-
1,00 миң
EBT including unusual items
-9,90 млн
-10,52 млн
-10,52 млн
-11,56 млн
EBT excluding unusual items
-9,90 млн
-10,52 млн
-10,52 млн
-11,56 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-288,00 миң
Net income
-9,90 млн
-10,52 млн
-10,52 млн
-11,56 млн
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
154,00 миң
231,00 миң
34,00 миң
-
Interest expense
-
-
-
-
Net interest expenses
154,00 миң
231,00 миң
34,00 миң
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-9,35 млн
-10,21 млн
-10,77 млн
-11,10 млн
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору